Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test

Souza, Lisiane de Santana; Silva, E.F.; Santos, Wilton B.; Asth, Laila; Lobão-Soares, Bruno; Soares-Rachetti, Vanessa P.; Medeiros, Iris Ucella de; Gavioli, Elaine C.

doi:10.1016/j.neulet.2016.06.044

Cited by 16 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Work by D'Andrea et al (2015) showed that LC neuronal dysfunction by CREB signaling hyperactivity cause ADHD-like behavior in PI3Kγ conventional knockout (PI3Kγ KO) mice. Since ADHD and mania animal models have overlapped behavioral phenotypes ( Beyer and Freund, 2017 ; Itohara et al, 2015 ), we treated ErbB4-deficient mice with methylphenidate (MHP), a clinical ADHD medication which alleviates hyperactivity of ADHD animal models but aggravates hyperactivity of mania models ( D'Andrea et al, 2015 ; Souza et al, 2016 ; Sumitomo et al, 2018 ). Our results showed that MHP aggravated hyperactivity of ErbB4-deficient ( Erbb4 loxp/loxp + AAV-Cre-GFP) mice ( Figure 5—figure supplement 3 ).…”

Section: Discussionmentioning

confidence: 99%

ErbB4 deletion in noradrenergic neurons in the locus coeruleus induces mania-like behavior via elevated catecholamines

Cao

Zhang

et al. 2018

eLife

View full text Add to dashboard Cite

Dysfunction of the noradrenergic (NE) neurons is implicated in the pathogenesis of bipolar disorder (BPD). ErbB4 is highly expressed in NE neurons, and its genetic variation has been linked to BPD; however, how ErbB4 regulates NE neuronal function and contributes to BPD pathogenesis is unclear. Here we find that conditional deletion of ErbB4 in locus coeruleus (LC) NE neurons increases neuronal spontaneous firing through NMDA receptor hyperfunction, and elevates catecholamines in the cerebrospinal fluid (CSF). Furthermore, Erbb4-deficient mice present mania-like behaviors, including hyperactivity, reduced anxiety and depression, and increased sucrose preference. These behaviors are completely rescued by the anti-manic drug lithium or antagonists of catecholaminergic receptors. Our study demonstrates the critical role of ErbB4 signaling in regulating LC-NE neuronal function, reinforcing the view that dysfunction of the NE system may contribute to the pathogenesis of mania-associated disorder.

show abstract

Section: Discussionmentioning

confidence: 99%

ErbB4 deletion in noradrenergic neurons in the locus coeruleus induces mania-like behavior via elevated catecholamines

Cao

Zhang

et al. 2018

eLife

View full text Add to dashboard Cite

show abstract

“…Administration of MPH and ALZ alone and in combination for 4 weeks significantly reduced the body weights, which might be due to loss of appetite and increased locomotor activity associated with MPH administration. [ 17 18 ] On the other hand, the fall in bodyweight of ALZ and A + M treated rats might be as a result of increased energy expenditure due to hyperlocomotion and excessive loss of water through increased frequency of defecation and urination. [ 19 ] However, there were no significant differences in the food and water intake levels.…”

Section: Discussionmentioning

confidence: 99%

Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate

et al. 2020

View full text Add to dashboard Cite

OBJECTIVE: Methylphenidate (MPH) is a first-line treatment option for attention-deficit hyperactive disorder and narcolepsy. MPH is one of the most abused psychostimulants by the adults and young population to stay awake, perform better, or improve concentration. The scanty reports say that the medical users or abusers mostly consider the administration of benzodiazepines to overcome the adverse effects, i.e., mood- and anxiety-related problems associated with MPH chronic abuse. This work aims to study the effect of alprazolam (ALZ) on MPH-associated adverse effects on liver and kidney. MATERIALS AND METHODS: Female Wistar rats ( n = 58) were administered with MPH (10, 20, and 40 mg/kg) and ALZ (5, 10, and 20 mg/kg) alone and in combination for 28 days. Bodyweight, feed intake, and water intake were monitored weekly. Parameters related to liver and renal function, oxidative stress, and histopathology were performed to evaluate the toxic impacts on the liver and kidneys. RESULTS: ALZ, along with MPH, increased the serum alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, creatinine, and urea levels. The co-abuse also led to elevated oxidative stress and structural abnormalities in the liver and kidney tissues. CONCLUSION: The co-abuse of ALZ has amplified the hepato-renal toxic effects of MPH. Therefore, it is a significant concern for public safety, and their co-abuse must be restricted and discouraged.

show abstract

“…The doses of VPA employed in our study have been previously reported in the literature to prevent mania-like behavior in rodents. 29,30 All injections were performed between ZT3 and ZT4 (10:00-11:00 AM).…”

Section: Drug Treatmentsmentioning

confidence: 99%

Valproate Reverses Mania-Like Behavior of Clockdelta19 Mouse and Alters Monoamine Neurotransmitters Metabolism in the Hippocampus

Li¹,

Wei²,

Ni³

et al. 2021

NDT

View full text Add to dashboard Cite

Background: Mice with a deletion at exon 19 of the circadian locomotor output cycles Kaput gene (Clock delta19) exhibit mania-like behavior and have been one of the most common animal models for bipolar disorder (BD). The predictive validity of the Clock delta19 was investigated via studies using lithium previously. Determination of effects of other mood stabilizers on Clock delta19 mouse would be helpful for better understanding of the mechanism underlined. Methods: Wildtype (WT) and Clock delta19 mice were treated with saline (n = 10 for WT and n=10 for Clock delta19) or valproate (VPA) (n = 10 for WT and n=10 for Clock delta19) for 10 days. The hyperactivity, anxiety-like behaviors and depression-like behaviors were tested. The concentration of monoamine neurotransmitters and their metabolites in the hippocampus of saline or VPA treated WT and Clock delta19 mouse (n = 8 for each) were also determined. Results: VPA can reverse hyperactivity, lower level of anxiety-like and depression-like behaviors of the Clock delta19 mouse. Clock delta19 mouse exhibited lower levels of serotonin (5-HT) and dopamine (DA) in right hippocampus compared to WT mouse. Chronic VPA treatment did not affect the levels of 5-HT and DA, but can reduce the level of levodopa (L-DOPA) in the right hippocampus of Clock delta19 mouse. Conclusion: Our results indicated that chronic VPA treatment can reverse the mania-like behaviors of the Clock delta19 mouse and further consolidate the validity of the Clock delta19 mouse as a model of BD. Monoamine neurotransmitters and their metabolites in the hippocampus are partly regulated by mutation of the Clock gene or VPA treatment.

show abstract

Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test

Cited by 16 publications

References 25 publications

ErbB4 deletion in noradrenergic neurons in the locus coeruleus induces mania-like behavior via elevated catecholamines

ErbB4 deletion in noradrenergic neurons in the locus coeruleus induces mania-like behavior via elevated catecholamines

Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate

Valproate Reverses Mania-Like Behavior of Clockdelta19 Mouse and Alters Monoamine Neurotransmitters Metabolism in the Hippocampus

Contact Info

Product

Resources

About